Multi-Modality Therapy for Advanced Esophageal Cancer
Orlistat treatment should be continued beyond 12 weeks only if the person has lost at least 5% of their initial body weight
The somatostatin neurons in the periventricular nucleus mediate negative feedback effects of growth hormone on its own release
In 2026, a new oral Wegovy pill and expanded WeightWatchers Med+ platform are making the weight loss treatment more accessible than ever for eligible patients
Organizations involved: payers/insurers, hospital specialty clinics, retail and online pharmacies, patient advocacy groups, specialty pharmacies, telemedicine providers, pharma patient-support teams, digital health vendors (adherence apps, remote monitoring), and third-party benefits managers